These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8297546)

  • 21. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
    Herd JA; West MS; Ballantyne C; Farmer J; Gotto AM
    Am J Cardiol; 1994 May; 73(14):42D-49D. PubMed ID: 8198024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
    Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin.
    Garnett WR; Venitz J; Wilkens RC; Dimenna G
    Am J Med; 1994 Jun; 96(6A):84S-86S. PubMed ID: 8017472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC.
    Siekmeier R; Lattke P; Mix C; Park JW; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):137-45. PubMed ID: 11509920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
    Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
    Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database.
    Peters TK; Mehra M; Muratti EN
    Am J Hypertens; 1993 Nov; 6(11 Pt 2):340S-345S. PubMed ID: 8297542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
    Spence JD; Munoz CE; Hendricks L; Latchinian L; Khouri HE
    Am J Cardiol; 1995 Jul; 76(2):80A-83A. PubMed ID: 7604806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
    Ceska R
    Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
    Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
    Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
    Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit.
    Tse FL; Labbadia D
    Biopharm Drug Dispos; 1992 May; 13(4):285-94. PubMed ID: 1600114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies.
    Lanchote VL; Rocha A; de Albuquerque FU; Coelho EB; Bonato PS
    J Chromatogr B Biomed Sci Appl; 2001 Dec; 765(1):81-8. PubMed ID: 11817313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
    Appel S; Rüfenacht T; Kalafsky G; Tetzloff W; Kallay Z; Hitzenberger G; Kutz K
    Am J Cardiol; 1995 Jul; 76(2):29A-32A. PubMed ID: 7604792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys.
    Hartman HA; Myers LA; Evans M; Robison RL; Engstrom RG; Tse FL
    Fundam Appl Toxicol; 1996 Jan; 29(1):48-62. PubMed ID: 8838639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.